TRIS-Free Lentiviral Vector Formulations for Storage Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing lentiviral vector formulations are unstable under various conditions, leading to structural degradation and loss of biological activity, which complicates their use in gene therapy and vaccine development.
Innovation Solution
Formulations comprising a TRIS-free buffer system, such as phosphate or histidine buffer, combined with a carbohydrate like sucrose, a surfactant like poloxamer or polysorbate, and a salt like NaCl, stabilize lentiviral vectors and maintain their structural integrity and potency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If lentiviral vectors are stored under various conditions (agitation, freeze/thawing, temperature fluctuations), then their structural integrity and biological activity deteriorate, but storage stability is required for practical gene therapy applications
Solution Approach 1:
The patent optimizes formulation parameters including pH (6.0-7.5), buffer composition (TRIS-free systems like phosphate or histidine), excipient concentrations (surfactants, carbohydrates, salts), and storage temperature to maintain lentiviral vector stability. These parameter changes prevent degradation while preserving biological activity during storage and handling
Solution Approach 2:
The patent introduces formulation excipients as intermediary substances that protect lentiviral vectors from environmental stressors. These include surfactants (poloxamer, polysorbate) that prevent aggregation, carbohydrates (sucrose, mannitol) that stabilize structure, and buffers that maintain pH, thereby mediating protection between the vectors and destabilizing conditions
2Stability of the object's composition
If conventional formulations are used, then manufacturing is simpler, but the formulations fail to provide adequate stability under storage and handling conditions
Solution Approach 1:
The patent develops composite formulations combining multiple excipients (surfactants, carbohydrates, salts, buffers) with lentiviral vectors to create a stable pharmaceutical composition. This composite approach provides enhanced stability under various conditions while maintaining manageable manufacturing complexity through optimized component ratios
3Reliability
If pH is adjusted to stabilize surface proteins, then lentiviral vector disassembly is prevented, but improper pH causes protein destabilization and vector breakdown
Solution Approach 1:
The patent precisely controls pH within the 6.0-7.5 range using TRIS-free buffer systems to maintain lentiviral vector stability. This parameter optimization prevents both vector disassembly and protein destabilization, achieving optimal protection without the harmful effects of improper pH adjustment
Data Source
AI summary
Lentiviral vector (LV) formulations, and pharmaceutical compositions comprising such LV formulations, with improved stability and suitable for systemic administration are provided. Methods for treating disorders, especially blood disorders, using systemic administration of LV formulations are also provided.